
STOK Stock Forecast & Price Target
STOK Analyst Ratings
Bulls say
Stoke Therapeutics is a biotechnology company with a promising pipeline and a unique approach to treating genetic diseases through up-regulation of protein expression. Their lead candidate, zorevunersen, has shown potential for disease modification in patients with Dravet syndrome and has been granted FDA Breakthrough Therapy designation. The company's TANGO technology has the potential to address hundreds of disease states caused by haploinsufficiencies. While there are risks involved in drug discovery and development, Stoke has a strong potential for success in the market, with a peak annual sales estimate of $1 billion for zorevunersen.
Bears say
Stoke Therapeutics is a biotechnology company that utilizes RNA medicine to restore protein levels and treat genetic disorders. However, the company has experienced large operating losses and net losses in recent quarters, and it may struggle to obtain FDA approval for its lead asset, zorevunersen, due to concerns over the drug's ability to effectively treat Dravet syndrome. Additionally, Stoke faces potential risks related to stock price volatility, financial stability, and intellectual property rights. Considering these factors, the company's stock may not be a profitable investment at this time.
This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
STOK Analyst Forecast & Price Prediction
Start investing in STOK
Order type
Buy in
Order amount
Est. shares
0 shares